TTT-3002

TTT-3002 is a highly potent investigational small molecule indolocarbazole kinase inhibitor developed principally for the treatment of acute myeloid leukemia (AML) with FLT3 mutations. It functions as an inhibitor of the FMS-like tyrosine kinase 3 (FLT3), especially targeting both internal tandem duplication (FLT3/ITD) and tyrosine kinase domain (e.g., D835, F691L) mutations—including those conferring resistance to earlier tyrosine kinase inhibitors (TKIs)[1][2][3][4][5][7][8]. TTT-3002 inhibits FLT3 phosphorylation and downstream effectors such as STAT5, AKT, and MAPK, thereby blocking leukemic cell proliferation and survival. It has demonstrated preclinical efficacy both in vitro and in vivo (murine models), including ability to eliminate leukemic blasts and overcome resistance to other FLT3 TKIs[1][2][3][4][5]. Early studies show it is only moderately protein-bound in plasma, suggesting durable pharmacodynamic effects[4][5].